Serum insulin like growth factor-1 (IGF-1) and insulin like growth factor binding protein-3 (IGFBP-3) levels in liver cirrhosis

Turkish Journal of Gastroenterology

Volumn 18, Issue 4, 2007, Pages 245-249

  Çolakoǧlu, Önder ^a   Taşkiran, Bengür ^b   Çolakoǧlu, Gül ^c   Kizildaǧ, Servet ^d   Ari Özcan, Fulya ^a   Ünsal, Belkis ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b TRAKYA UNIVERSITY   (Turkey)

^c Izmir Tepecik Training and Research Hospital   (Turkey)

^d DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Child class; IGF 1; IGFBP 3; Liver cirrhosis

Indexed keywords

ALBUMIN; ALCOHOL; CREATININE; POTASSIUM; SODIUM; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C; UREA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DIAGNOSTIC IMAGING; DIGESTIVE TRACT ENDOSCOPY; FEMALE; HEIGHT; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MALE; PROTEIN BLOOD LEVEL; RATING SCALE; SEX; SPLEEN SIZE; STATISTICAL SIGNIFICANCE; WEIGHT;

ADULT; AGED; CREATININE; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; ORGAN SIZE; SERUM ALBUMIN; SODIUM; SPLEEN; YOUNG ADULT;

EID: 43549104721     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Schwander JC, Hauri C, Zapf J, Froesch ER. Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 1983; 113: 297-305.
2. Garcia-Fernandez M, Castilla-Cortazar I, Diaz-Sanchez M, et al. Effect of IGF-1 on total serum antioxidant status in cirrhotic rats. J Physiol Biochem 2003; 59: 145-6.
3. Muguerza B, Castilla-Cortazar I, Garcia M, et al. Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats. Biochim Biophys Acta 2001; 1536: 185-95.
4. Donaghy AJ, Delhanty PJ, Ho KK, et al. Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. J Hepatol 2002; 36(6): 751-8.
5. Ottesen LH, Bendtsen F, Flyvbjerg A. The insulin-like growth factor binding protein 3 ternary complex is reduced in cirrhosis. Liver 2001; 21(5): 350-6.
6. Assy N, Hochberg Z, Amit T, et al. Growth hormone-stimulated insulin-like growth factor (IGF) I and IGF-binding protein-3 in liver cirrhosis. J Hepatol 1997; 27(5): 796-802.
7. Moller S, Juul A, Becker U, et al. Concentrations, release, and disposal of insulin-like growth factor (IGF)-binding proteins (IGFBP), IGF-1, and growth hormone in different vascular beds in patients with cirrhosis. J Clin Endocrinol Metab 1995; 80(4): 1148-57.
8. Donaghy A, Ross R, Gimson A, et al. Growth hormone, insulinlike growth factor-1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology 1995 Mar; 21(3): 680-8.
9. Wu YL, Ye J, Zhang S, et al. Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol 2004; 10(18): 2740-3.
10. Mendenhall CL, Chernausek SD, Ray MB, et al. The interactions of insulin-like growth factor-1 (IGF-1) with protein-calorie malnutrition in patients with alcoholic liver disease: V.A. Cooperative Study on Alcoholic Hepatitis VI. Alcohol Alcohol 1989; 24: 319-29.
11. Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, et al. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab 2004; 89(9): 4325-30.
12. Mendenhall CL, Roselle GA, Gartside P, Grossman CJ. Effects of recombinant human insulin-like growth factor-1 and recombinant human growth hormone on anabolism and immunity in calorie restricted alcoholic rats. Alcohol Clin Exp Res 1997; 21: 1-10.
13. Mattera D, Capuano G, Colao A, et al. Increased IGF-1: IGFBP-3 ratio in patients with hepatocellular carcinoma. Clin Endocrinol (Oxf) 2003 Dec; 59(6): 699-706.
14. Shmueli E, Miell JP, Stewart M, et al. High insulin-like growth factor binding protein 1 levels in cirrhosis: link with insulin resistance. Hepatology 1996; 24(1): 127-33.
15. Kratzsch J, Blum WF, Schenker E, Keller E. Regulation of growth hormone (GH), insulin-like growth factor (IGF)I, IGF binding proteins -1, -2, -3 and GH binding protein during progression of liver cirrhosis. Exp Clin Endocrinol Diabetes 1995; 103(5): 285-91.
16. Vyzantiadis T, Theodoridou S, Giouleme O, et al. Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis. Hepatogastroenterology 2003; 50(51): 814-6.
17. Caregaro L, Alberino F, Amodio P, et al. Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. Nutrition 1997; 13(3): 185-90.
18. Borroni G, Maggi A, Sangiovanni A, et al. Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Dig Liver Dis 2000; 32(7): 605-10.
19. Hirschberg R, Brunori G, Kopple JD, Guler HP. Effects of insulin-like growth factor I on renal function in normal men. Kidney Int 1993; 43: 387-97.
20. Guler HP, Eckardt KU, Zapt J, et al. Insulinlike growth factor increases glomerular filtration rate and renal plasma flow in man. Acta Endocrinol 1989; 121: 101-6.
21. Miller SB, Moulton M, O'Shea M, Hammerman MR. Effects of IGF-I on renal function in end-stage chronic renal failure. Kidney Int 1994; 46: 201-7.
22. O'Shea M, Miller SB, Hammerman MR. Effect of IGF-I on renal function in patients with chronic renal failure. Am J Physiol 1993; 264(5 Pt 2): F917-22.
23. Blomsma MC, de Knegt RJ, Dullaart RPF, Jansen PLM. Insulin-like growth factor in cirrhosis. J Hepatol 1997; 27: 1133-8.
24. Moller J, Jorgensen JO, Marqversen J, et al. Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: possible involvement of renin and atrial natriuretic factor. Clin Endocrinol (Oxf) 2000; 52: 181-6.
25. Feld S, Hirschberg R. Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev 1996; 17: 423- 80.
26. Fernandez-Rodriguez CM, Prada I, Andrade A, et al. Disturbed synthesis of insulinlike growth factor I and its binding proteins may influence renal function changes in liver cirrhosis. Dig Dis Sci 2001; 46(6): 1313-20.
27. Shapiro MD, Nicholls KM, Groves BM, et al. Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients. Kidney Int 1985; 2: 206-11.
28. Ginès P, Fernández-Esparrach G, Arroyo V, Rodés J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17: 175-89.
29. Cemborain A, Castilla-Cortazar I, Garcia M, et al. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol 1998; 28: 122-31.
30. Picardi A, de Oliveira AC, Muguerza B, et al. Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis. J Hepatol 1997; 26: 191-202.
31. Castilla-Cortazar I, Garcia M, Muguerza B, et al. Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride- induced cirrhosis Gastroenterology 1997; 113: 1682-91.